Fold Holdings, Inc. (FLD) is a dynamic biotechnology firm focused on developing revolutionary therapies for severe genetic and rare diseases through cutting-edge research. The company boasts a promising product pipeline underpinned by proprietary technologies and strategic partnerships that enhance its competitive positioning in the market. Committed to scientific excellence and patient-centered solutions, Fold is poised for sustainable growth and value creation, making it a compelling investment opportunity in the evolving healthcare landscape.
| Revenue (TTM) | $31.79M |
| Gross Profit (TTM) | $-15.59M |
| EBITDA | $-28.22M |
| Operating Margin | -90.20% |
| Return on Equity | 278.60% |
| Return on Assets | -12.80% |
| Revenue/Share (TTM) | $0.75 |
| Book Value | $1.30 |
| Price-to-Book | 0.94 |
| Price-to-Sales (TTM) | 1.84 |
| EV/Revenue | 4.088 |
| EV/EBITDA | 4.04 |
| Quarterly Earnings Growth (YoY) | 1622.00% |
| Quarterly Revenue Growth (YoY) | 41.20% |
| Shares Outstanding | $50.82M |
| Float | $6.70M |
| % Insiders | 71.33% |
| % Institutions | 15.03% |
Volatility is currently contracting